RSV is responsible for around 1 lakh deaths, over 3.6 million hospitalisations in children under age of 5 every year, ...

When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to ...

Respiratory syncytial virus (RSV) is the number one cause of hospitalization in infants, accounting for about 25% of all ...

Nirsevimab implementation in Catalonia, Spain, reduced emergency department visits and hospital admissions for bronchiolitis ...

June 2, 2025 - Last Friday, the World Health Organization (WHO) published its first-ever position paper on immunization ...

Adults hospitalized for RSV face higher odds of cardiac complications than those with COVID-19 or influenza, especially in ...

The announcement comes as part of WHO’s broader effort to reduce child mortality, particularly in low- and middle-income ...

A single dose of the long-acting antibody nirsevimab to infants can halve hospitalizations for bronchiolitis.

Discover a study that highlights the importance of identifying high-risk children through biomarkers and better understanding ...

The product is a new vaccine against COVID-19, for use in all adults 65 and older, as well as individuals aged 12-64 years.